Accessibility Menu
Shanghai Henlius Biotech logo

Shanghai Henlius Biotech(SEHK) 2696

Market CapHK$38.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)+42%
5 Year+143%
1 Year-15%
1 Month+19%
HK$66.20
+0.30%
+0.20Today
Shanghai Henlius Biotech last closing stock price
MetricPriceDate
Last closeHKD 66.002026-08-31
Shanghai Henlius Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.76%HKD 65.502026-08-24
1 month+18.6%HKD 55.652026-07-31
3 month+12.53%HKD 58.652026-06-02
Year to date+15.69%HKD 57.052025-12-31
1 year-15.28%HKD 77.902025-08-29
3 year+450%HKD 12.002023-08-31
5 year+143.09%HKD 27.152021-09-01
Since inception+41.86%HKD 49.452019-09-25

Shanghai Henlius Biotech Financials at a Glance

Market Cap

HK$38.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥6.67B

Net Income (TTM)

CN¥827.04M

EPS (TTM)

HK$1.77

P/E Ratio

39.35

Dividend

HK$0.00

Beta (Volatility)

0.02 (Low)

Price

HK$66.20

Volume

125,409

Open

HK$65.00

Previous Close

HK$66.00

Daily Range

HK$65.00 - HK$66.80

52-Week Range

HK$50.25 - HK$92.00

Estimated Earnings Date

Mar 19, 2027

2696 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc. is a biopharmaceutical enterprise focused on the research and development of biologic medicines, primarily targeting cancer, autoimmune conditions, and ophthalmic disorders. The company has a diverse portfolio of approved biologic treatments and a robust pipeline of investigational compounds.

Products and Services
  • HANLIKANG: Rituximab injection for non-Hodgkin lymphoma and rheumatoid arthritis
  • HANQUYOU: Trastuzumab injection for breast and gastric cancer
  • HANDAYUAN: Adalimumab injection for various autoimmune diseases
Growth Outlook
  • Strong pipeline with multiple investigational compounds targeting solid tumors
  • Recent quarterly revenue of CNY 1.92 billion indicates robust market demand
  • Expansion into international markets enhances growth potential
Financial Highlights
  • Trailing twelve months (TTM) revenue of CNY 7.5 billion reflects consistent growth
  • Net income margin of 12.41% demonstrates effective cost management
  • Operating cash flow of CNY 267 million in the latest quarter supports operational stability
Shanghai Henlius Biotech, Inc. operates in a competitive biotechnology sector, leveraging its innovative research capabilities to develop treatments for serious health conditions. The company's focus on biologic medicines positions it well to capitalize on the growing demand for advanced therapies. Recent financial performance highlights a strong revenue trajectory and effective cost management, which may appeal to potential investors. The ongoing development of its product pipeline and expansion into new markets further enhances its growth prospects, making it a noteworthy entity in the biopharmaceutical landscape.
AI Generated • Aug 12, 2026

Industry

Biotechnology

Sector

Health Care

Employees

3,762

CEO

Jun Zhu, EMBA

Website

www.henlius.com

Headquarters

Shanghai, SH 200233, CN

2696 Financials

Key Financial Metrics (TTM)

Gross Margin

74.66%

Operating Margin

12.26%

Net Income Margin

12.41%

Return on Equity

22.45%

Return on Capital

10.81%

Return on Assets

6.69%

Earnings Yield

2.54%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$38.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

545.26M

Volume

125.41K

Avg. Volume

871.55K

Financials (TTM)

Gross Profit

CN¥4.98B

Operating Income

CN¥817.12M

EBITDA

CN¥1.12B

Operating Cash Flow

CN¥1.31B

Capital Expenditure

-CN¥311.37M

Free Cash Flow

CN¥994.25M

Cash & ST Invst.

CN¥772.21M

Total Debt

CN¥3.60B

Shanghai Henlius Biotech Performance Analysis

Shanghai Henlius Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 3,738,339,42984.4%
20232023-12-31CNY 5,961,363,64059.5%
20242024-12-31CNY 6,206,584,0914.1%
20252025-12-31CNY 7,230,112,78516.5%
Shanghai Henlius Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-5.3%
Q22025-06-30N/A
Q32025-09-3036.4%
Q42025-12-31N/A
Shanghai Henlius Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -1.49-32.2%
20232023-12-31CNY 1.11N/A
20242024-12-31CNY 1.6448.1%
20252025-12-31CNY 1.640.4%
Shanghai Henlius Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12025-03-31-10.0%
Q22025-06-30N/A
Q32025-09-308.3%
Q42025-12-312.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

CN¥1.92B

+29.2%

Gross Profit

CN¥1.39B

+27.0%

Gross Margin

72.41%

N/A

Market Cap

HK$38.25BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$10.17M

N/A

Employees

3,762

N/A

Net Income

CN¥218.46M

+0.6%

EBITDA

CN¥270.83M

-3.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

CN¥772.21M

-0.1%

Total Debt

CN¥3.60B

-1.4%

Accounts Receivable

CN¥1.83B

+103.4%

Inventory

CN¥612.41M

-15.9%

Long Term Debt

CN¥1.35B

+24.0%

Short Term Debt

CN¥2.25B

-12.2%

Return on Assets

6.69%

N/A

Return on Invested Capital

11.01%

N/A

Free Cash Flow

CN¥198.35M

-57.4%

Operating Cash Flow

CN¥267.38M

-46.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 2696

What is the current price of Shanghai Henlius Biotech?

Shanghai Henlius Biotech is trading at HK$66.20 per share.

What is the 52-week range for Shanghai Henlius Biotech?

Over the past 52 weeks, Shanghai Henlius Biotech has traded between HK$50.25 and HK$92.00.

How much debt does Shanghai Henlius Biotech have?

As of the most recent reporting period, Shanghai Henlius Biotech reported total debt of CN¥4.01B.

How much cash does Shanghai Henlius Biotech have on hand?

Shanghai Henlius Biotech reported CN¥645.13M in cash and cash equivalents in its most recent financial results.

What is Shanghai Henlius Biotech’s dividend yield?

Shanghai Henlius Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services